Advanced CAR-T Cell Therapy for B-Cell Cancers
Trispecific CAR-T cells targeting CD19, CD20 and CD22 to treat B-cell malignancies
This project is developing a new type of CAR-T cell therapy to better treat B-cell cancers like lymphoma and leukemia, especially for patients whose cancer has returned.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11105967 on NIH RePORTER |
What this research studies
Current CAR-T cell therapies have been very helpful for B-cell cancers, but some patients still experience their cancer coming back. This happens either because the cancer cells lose their target markers or because the CAR-T cells don't last long enough or stop working. Our project is creating a new, advanced CAR-T cell therapy that targets three different markers on cancer cells (CD19, CD20, and CD22) instead of just one. It also includes a special feature (OX-40) designed to help the CAR-T cells stay active and effective for a longer time. We hope this new approach will overcome the limitations of current treatments and provide more lasting remissions for patients.
Who could benefit from this research
Good fit: Ideal candidates would be patients with B-cell non-Hodgkin's lymphoma or B-cell acute lymphoblastic leukemia, particularly those whose cancer has returned after previous treatments.
Not a fit: Patients with cancers other than B-cell malignancies or those who do not have the specific target antigens may not receive benefit from this particular therapy.
Why it matters
Potential benefit: If successful, this new CAR-T cell therapy could offer more durable remissions and reduce the chance of relapse for patients with B-cell malignancies.
How similar studies have performed: Previous preclinical work has shown significant activity for this trispecific CAR-T cell approach compared to existing single-target CAR-T cells.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Vasu, Sumithira — Ohio State University
- Study coordinator: Vasu, Sumithira
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.